Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints

Alterations in the response of leukaemic cells to apoptosis-inducing stimuli may account for resistance to chemotherapy and treatment failure, either by disruption of the apoptotic pathway itself or by altered DNA repair; quiescent cells and those with disrupted cell-cycle checkpoints may also display decreased apoptosis. Quiescence can be induced by the differentiation of myeloid cells, and this led us to investigate whether the modulation of drug-induced apoptosis associated with differentiation might be a model for quiescence-associated resistance generally. We have demonstrated that resistance to idarubicin-induced apoptosis increased with greater duration of incubation of HL60 and U937 cells with ATRA and 1,25(OH)2 D3 and that this protective effect correlated with the degree of G0/G1 accumulation. In addition, the cytoprotective effects held for other classes of cytotoxic drugs with different mechanisms of action to idarubicin. Prolonged exposure to idarubicin or vinblastine was associated with diminution of the protective effect and re-entry of cells into cycle. The full cytoprotective effect was restored by resupplementation with ATRA or 1,25(OH)2 D3 during exposure to idarubicin, with concomitant persistence of G0/G1 accumulation. Differentiating agents prevented the accumulation of leukaemic cells at the G2/M checkpoint in response to low concentrations of idarubicin. Understanding how differentiating agents modulate these cell-cycle checkpoints, and how quiescent cells evade apoptosis, may allow the development of therapeutic strategies to limit such apoptosis-inhibiting effects and maximise cell kill from chemotherapy.

[1]  P. Allen,et al.  Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. , 1997, Blood.

[2]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[3]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Kufe,et al.  Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. , 1991, Cancer research.

[5]  T. Cotter,et al.  Cell Death in the Myeloid Lineage , 1994, Immunological reviews.

[6]  M. Birrer,et al.  The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  M. Minden,et al.  Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. , 1993, Leukemia.

[8]  M. Tallman.  Differentiating therapy in acute myeloid leukemia. , 1996, Leukemia.

[9]  Koichi Sugimoto,et al.  Frequent mutations in the p53 gene in human myeloid leukemia cell lines. , 1992, Blood.

[10]  Z. Su,et al.  Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. , 1994, Oncogene.

[11]  P. Fenaux,et al.  Treatment of acute promyelocytic leukaemia. , 2001, Best practice & research. Clinical haematology.

[12]  E. McCulloch.  Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982) , 1983 .

[13]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[14]  H. Koeffler,et al.  Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. , 1986, The Journal of clinical investigation.

[15]  R. Gale,et al.  GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. , 1990, Leukemia research.

[16]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.

[17]  D. Kufe,et al.  Internucleosomal DNA fragmentation during phorbol ester-induced monocytic differentiation and G0/G1 arrest. , 1992, The Journal of clinical investigation.

[18]  L. Daniel,et al.  1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. , 1994, The Journal of biological chemistry.

[19]  J. Lotem,et al.  Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. , 1992, Blood.

[20]  H. Hidaka,et al.  Protein kinase C activation and protooncogene expression in differentiation/retrodifferentiation of human U-937 leukemia cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  H P Koeffler,et al.  Differentiation therapy. , 1992, Hematology/oncology clinics of North America.

[22]  C. Tepper,et al.  1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. , 1993, Experimental cell research.

[23]  L. Gordon,et al.  All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia: update of an illinois cancer center phase d pilot study , 1996 .

[24]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[25]  R. Pirker,et al.  Clinical relevance of drug resistance genes in malignant disease. , 1996, Leukemia.

[26]  I. Olsson,et al.  Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3':5'-monophosphate-inducing agents. , 1982, Cancer research.

[27]  J. Griffin,et al.  Clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.

[28]  K. Kohn,et al.  Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. , 1993, Blood.

[29]  M. Andreeff,et al.  Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. , 1990, Leukemia.

[30]  Y. Hannun,et al.  Ceramide: A stress signal and mediator of growth suppression and apoptosis , 1995, Journal of cellular biochemistry.

[31]  C. Guillouf,et al.  Induction of p21 (WAF-1/CIP1) during differentiation. , 1994, Oncogene.

[32]  R. Schlegel,et al.  Apoptosis and the cell cycle , 1995, Journal of cellular biochemistry.

[33]  L. Zwelling,et al.  Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. , 1988, Cancer research.

[34]  John Calvin Reed,et al.  Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells , 1997, Leukemia.

[35]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[36]  D. Kufe,et al.  Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. , 1996, Blood.

[37]  M. Groudine,et al.  Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia , 1997 .

[38]  M. Tribalto,et al.  All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. , 1995, Leukemia.

[39]  J. Marie,et al.  P-glycoprotein in adult hematologic malignancies. , 1995, Hematology/oncology clinics of North America.

[40]  R. Weichselbaum,et al.  Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[41]  J. Jones,et al.  Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. , 1996, Cancer research.

[42]  Y-M Zhu,et al.  Down‐regulation of bcl‐2 in AML blasts by all‐trans retinoic acid and its relationship to CD34 antigen expression , 1996, British journal of haematology.

[43]  Z. Darżynkiewicz,et al.  Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. , 1994, Leukemia.

[44]  G. P. Studzinski,et al.  Potentiation of 1-beta-D-arabinofuranosylcytosine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D3 correlates with reduced rate of maturation of DNA replication intermediates. , 1991, Cancer research.

[45]  U. Gullberg,et al.  Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells. , 1996, Blood.

[46]  N. Abraham,et al.  Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH)2 vitamin D3. , 1991, Leukemia research.

[47]  K. Scotto,et al.  Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals , 1995, Cell.

[48]  L. Freedman,et al.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.